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Abstract
Background: Controlled attenuation parameter (CAP) is a recently introduced, non-invasive and quantitative
method to evaluate hepatic steatosis demonstrated in adults, but limited in obesity and not well evaluated in
children. The aim of this study was to investigate the diagnostic performance for assessing hepatic steatosis grades
using CAP in children based on MR proton density fat fraction (PDFF).
Methods: Children evaluated for non-alcoholic fatty liver disease (NAFLD) who were assessed for PDFF and CAP were
enrolled retrospectively. Hepatic steatosis grades 0–3 were classified according to PDFF using cutoff values of 6, 17.5, and
23.3%. Subgroup analyses were performed in non-obese and obese groups using the 95th percentile body mass index
(BMI) as a cutoff and BMI30 group when BMI > 30 kg/m2. Pearson’s correlations between variables were also analyzed.
Results: In a total of 86 children, there were 53 in the obese group including 17 of the BMI30 group. CAP demonstrated
98.7% sensitivity and 80% specificity for diagnosing grades 1–3 vs. grade 0 using a cutoff value of 241 dB/m (area under
the curve = 0.941, p < 0.001). The diagnostic performance for higher steatosis grades was suboptimal. CAP correlated with
abdominal wall thickness in both obese (r = 0.549, p = 0.001) and non-obese (r = 0.386, p = 0.004) groups and did not
correlate with PDFF in BMI30 group.
Conclusion: In children with NAFLD, CAP showed excellent diagnostic performance for differentiating presence and
absence of hepatic steatosis using a cutoff value of 241 dB/m. However, CAP was limited in evaluating grades of steatosis,
especially in children with BMI > 30 kg/m2.
Keywords: Fatty liver, Non-alcoholic fatty liver disease, Children, Controlled attenuation parameter, Proton density fat
fraction
Background
Non-alcoholic fatty liver disease (NAFLD) is the most
prevalent liver disease in children [1]. It has a large
spectrum of presentation, can progress, and is associated
with dyslipidemia, diabetes, and cardiovascular disease
[2]. The prevalence of NAFLD was reported by race and
ethnicity among a pediatric population as: Asian: 10.2%,
Black: 1.5%, Hispanic: 11.8%, and White: 8.6% [1]. With
worldwide increasing trends of obesity and consequently
NAFLD in children and adolescents, including South
Korea as the prevalence of obesity increased from 6.8%
in 1998 to 10.0% in 2013 [3, 4], there is increased risk of
liver, cardiovascular and metabolic diseases throughout
the lifespan. Although liver biopsy is the clinical stand-
ard for diagnosis, it is an invasive procedure with sam-
pling errors and questionable inter- and intra-observer
reliability [5]. Therefore, liver biopsy may not be ideal
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for all patients suspected of having NAFLD and for lon-
gitudinal follow-up, especially in children.
Non-invasive liver imaging techniques for hepatic stea-
tosis have been emerging as a substitute for liver biopsy.
MRI-estimated liver proton density fat fraction (PDFF)
has shown a good correlation with histologic steatosis
grade and the potential of clinical utility for the evaluation
of NAFLD in both adults and children [6, 7]. Moreover, it
not only has a high precision and reproducibility, but also
greater reliability than histologic grading [8]. In a multi-
center study for children with NAFLD, PDFF has shown
high diagnostic accuracy to classify and predict histo-
logical steatosis grade, as well as to monitor changes in
steatosis [9]. However, widespread use of PDFF might be
limited in pediatric clinics due to high cost with need for
expertise and longer examination time.
Transient elastography (TE) is an ultrasound-based
technology used to estimate quantitative liver elasticity
and is commonly used in clinical practice [10]. Con-
trolled attenuation parameter (CAP), a novel technique
to estimate hepatic steatosis using ultrasound attenu-
ation based on the TE, shows correlation with histologic
grades in adults [11–13]. Previous studies in pediatric
liver disease have also shown encouraging outcomes for
assessing steatosis using CAP [14]. CAP has advantages
over MRI in terms of cost, accessibility, and quick as-
sessment. However, the lack of optimal cutoff values for
hepatic steatosis and technical limitation in obese pa-
tients [15], which is a risk factor for NAFLD [16], still
remain in pediatric patients.
Therefore, in the present study, we aimed to evaluate
the diagnostic performance of CAP for assessing hepatic
steatosis in children based on PDFF with subgroup ana-
lyses based on body mass index (BMI).
Methods
Patients
This retrospective study was approved by the Institu-
tional Review Board of our hospital. The acquisition of
informed consent was waived. Pediatric patients aged 18
years or younger who underwent both abdominal MRI
including PDFF and TE with CAP as a routine clinical
practice for the evaluation of NAFLD in our hospital
were included in this study. We included only the exam-
inations within one month interval from January 2015 to
December 2016. We excluded patients who had clinical
or laboratory evidence of a liver diagnosis other than
NAFLD (e.g., glycogen storage disease, drug, or virus) or
alcohol consumption. We also reviewed laboratory re-
sults including aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels. Patients were di-
vided into non-obese and obese groups based on BMI
using the age and sex dependent 95th percentile as the
cutoff [17]. We also classified patients with a BMI
greater than 30 kg/m2 among the obese group as a sep-
arate BMI30 group for additional analysis.
Liver MRI including PDFF
All MR scans were performed with patients lying supine
in a 3-T scanner (Discovery MR750, GE Healthcare,
Waukesha, WI, USA) with a 32-channel body coil with-
out sedation. MR acquisition included single shot fast
spin echo (SSFSE) T2-weighted axial and coronal images
and iterative decomposition of water and fat with echo
asymmetry and least-squares estimation quantification
(IDEAL-IQ) axial images of the liver. SSFSE was used to
identify anatomical locations and lesions in the liver as
well as to measure abdominal wall thickness (AWT),
which was defined as the thinnest skin-to-liver capsule
distance of the abdominal wall surrounding the liver on
an axial image at the main portal vein level. The
IDEAL-IQ sequence is a three-dimensional volumetric
imaging sequence for creating water, fat, in-phase,
out-of-phase, R2* (1/T2*), and fat fraction (water-trigly-
ceride fat separation) maps of the liver from a single
breath hold acquisition. The parameters of IDEAL-IQ
were as follows: repetition time, 5.8 msec; field of view,
35–42 cm; bandwidth, 125 kHz; flip angle, 3°; section
thickness, 8 mm; and a single three-dimensional image
with 25 to 30 sections.
PDFF measurements in IDEAL-IQ were performed by
placing regions of interest (ROIs) with the maximal area
in the right hemiliver in three contiguous images. The
ROIs were oval or circular in shape and excluded the
liver boundary, fissures, gall bladder fossa, artifacts, and
large blood vessels. Finally, the average value of the three
measurements was used as the representative value. Pa-
tients’ steatosis grades were grouped according to the
established PDFF cutoff values for diagnosing histo-
logical steatosis grades 1 (S1), 2 (S2), and 3 (S3), and the
PDFF cutoff values used were 6% for S1, 17.5% for S2,
and 23.3% for S3 [9, 18].
TE for CAP
CAP measurements were performed using Fibroscan
(Echosens, France) by experienced technicians. TE was
performed on the right lobe of the liver through the
intercostal space with the participant lying supine with
the right arm in maximal abduction. All participants
underwent TE using an M or XL probe according to
body size. The M probe was used for patients with a
thoracic perimeter more than 75 cm, and the XL probe
was used when the distance from the skin to the liver
capsule was estimated over 25 mm. CAP measured ultra-
sonic attenuation at 3.5MHz in the M probe and 2.5
MHz in the XL probe using signals that were acquired
from TE. The median value of 10 valid measurements
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for a given participant was selected as the representative
CAP value.
Statistical analyses
Statistical analyses were performed using the SPSS soft-
ware package (IBM SPSS Statistics version 21; IBM
Corp., Armonk, NY, USA) and MedCalc software pack-
age (version 18.2.1; MedCalc Software, Ostend,
Belgium). Pearson’s correlation coefficient (r) was calcu-
lated to evaluate the correlations between variables. To
determine statistically significant differences in continu-
ous variables between the non-obese and obese BMI
groups, we used the one-way analysis of covariance with
sex and age as covariates. For the comparison of PDFF
and CAP in the BMI30 group, Mann Whitney test was
used. According to steatosis groups based on PDFF,
between-group differences were assessed by means of
the Kruskal-Wallis test. Bonferroni’s correction was ap-
plied to the post hoc analysis of the between-group com-
parison. Differences in categorical variables were
evaluated using the chi-square test or Fisher’s exact test
as appropriate. Correlation coefficients between groups
were compared with Fisher’s r-to-z transformation.
Receiver-operating curve (ROC) analysis was used to
evaluate the diagnostic performance of CAP for each
steatosis grade. The optimal cutoff values were selected
to maximize the Youden index. A p-value < 0.05 was
considered statistically significant.
Results
Patient characteristics
Table 1 shows the characteristics and laboratory results
of all study patients and each subgroup. A total of 86 pa-
tients (M: F = 62: 24) with a mean age of 13.1 ± 2.7 years
(range, 7–18 years) were included in this study. The time
interval between MRI and TE was 0–19 days with the
mean of 2.4 ± 5.0 days. Among the included patients, 33
were classified in the non-obese group, and the
remaining 53 patients belonged to the obese group.
Seventeen patients also met the criteria for inclusion in
the BMI30 group.
There was no significant difference in age or gender
between the non-obese and obese groups; however,
AWT was greater in the obese group compared to the
non-obese group (2.8 ± 0.6 cm vs. 2.1 ± 0.5 cm, p <
0.001). The mean AST (70.9 ± 53.2 IU/L vs. 46.2 ± 39.8
IU/L, p = 0.025) and ALT (119.0 ± 90.7 IU/L vs. 71.2 ±
66.9 IU/L, p = 0.011) values were significantly higher in
the obese group compared to the non-obese group. The
logarithmic transformed AST (1.77 ± 0.28 vs. 1.61 ± 0.32,
p = 0.015) and ALT (2.00 ± 0.29 vs. 1.72 ± 0.47, p = 0.004)
values were also significantly different between the two
groups. The other laboratory results were not signifi-
cantly different between the two groups (Table 1).
There was a positive correlation between AWT and
BMI (r = 0.807; 95% confidence interval [CI]: 0.718,
0.870). For the CAP assessment of TE, M and XL probes
Table 1 Patient characteristics including comparison between patients with a non-obese body mass index (BMI) (non-obese group)
and a BMI greater than the 95th percentile (obese group)
All patients
(n = 86)
Group comparison
Non-obese group (n = 33) Obese group (n = 53) p-value
Age (y) 13.1 ± 2.7 12.4 ± 2.4 13.5 ± 2.8 0.067
Female (n, %) 24 (31.3) 12 (36.4) 12 (22.6) 0.168*
BMI (kg/m2) 26.3 ± 4.9 21.6 ± 2.6 29.2 ± 3.5 < 0.001
AWT (cm) 2.5 ± 0.7 2.1 ± 0.5 2.8 ± 0.6 < 0.001
AST (U/L) 61.4 ± 49.7 46.2 ± 39.8 70.9 ± 53.2 0.015†
ALT (U/L) 100.7 ± 85.2 71.2 ± 66.9 119.0 ± 90.7 0.004†
Total bilirubin (mg/dL) 0.6 ± 0.3 0.5 ± 0.2 0.6 ± 0.3 0.861
Albumin (g/dL) 4.6 ± 0.3 4.6 ± 0.3 4.6 ± 0.2 0.702
ALP (IU/L) 206.5 ± 100.5 222.6 ± 99.0 196.5 ± 101.0 0.728
Cholesterol (mg/dL) 190.7 ± 35.9 185.8 ± 38.0 193.8 ± 34.5 0.229
TG (mg/dL) 159.5 ± 90.4 151.0 ± 86.0 163.3 ± 93.2 0.888†
HDL (mg/dL) 44.3 ± 10.0 45.8 ± 12.2 43.5 ± 8.7 0.501
LDL (mg/dL) 117.1 ± 34.4 113.9 ± 38.8 118.6 ± 32.3 0.356
PDFF (%) 22.6 ± 12.8 20.2 ± 14.5 24.1 ± 11.6 0.139
CAP (dB/m) 310.5 ± 46.5 293.6 ± 51.5 321.1 ± 40.2 0.053
* Chi-square test was performed to compare the two groups
†Logarithmic transformation before group comparison was performed in order to satisfy normality assumption. All the p-values of boldface are less than 0.05
Notes: AWT abdominal wall thickness, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, TG triglycerides, HDL high-density
lipoprotein, LDL low-density lipoprotein, PDFF proton density fat fraction, CAP controlled attenuation parameter
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were used for eighty-two and four patients, respectively.
The four patients used XL probe were all in the BMI30
group. Patient characteristics according to steatosis
group based on PDFF are summarized in Table 2.
Diagnostic performance of CAP
Both PDFF and CAP values were measured in all pa-
tients. The PDFF values ranged from 2.6–48.0% with a
mean of 22.6 ± 12.8%. The CAP values ranged from 157
to 400 dB/m with a mean of 310.5 ± 46.5 dB/m. Accord-
ing to PDFF, patients were divided into four steatosis
groups, S0 (PDFF < 6%, n = 10), S1 (PDFF 6–17.4%, n =
25), S2 (PDFF 17.5–23.2%, n = 14), and S3 (PDFF
≥23.3%, n = 37). The CAP values in each steatosis group
are shown in Fig. 1. The mean and median CAP values
were 228.4 ± 45.9 dB/m and 222.5 dB/m in S0, 309.0 ±
38.9 dB/m and 308 dB/m in S1, 313.2 ± 33.1 dB/m and
301 dB/m in S2, and 332.7 ± 28.3 dB/m and 329 dB/m in
S3, respectively. The mean CAP value of S0 showed a
statistically significant difference from the other groups
(p < 0.001), but there were no significant differences
among S1, S2, and S3.
In ROC analysis, a CAP value of 241 dB/m represented
an optimal cutoff value for diagnosis of S1–S3 vs. S0,
with a sensitivity of 98.7% (95% CI: 92.9, 100.0), a speci-
ficity of 80.0% (95% CI: 44.4, 97.5), and area under the
curve (AUC) of 0.941 (95% CI: 0.868, 0.980) (Table 3,
Fig. 1). Positive predictive value (PPV) and negative
predictive value (NPV) for the presence of steatosis on a
CAP value of 241 dB/m was 96.2 and 87.5%, respectively.
A CAP value of 213 dB/m showed 100% sensitivity (95%
CI: 95.3, 100.0) and 40% specificity (95% CI: 12.2, 73.8),
whereas a CAP value of 311 dB/m showed 57.9% sensi-
tivity (95% CI: 46.0, 69.1) and 100% specificity (95% CI:
69.2, 100.0) to diagnose the presence of steatosis. The
optimal CAP cutoff values of 299 dB/m and 303 dB/m
were obtained to predict S2–S3 vs. S0–S1 (sensitivity
80.4% with 95% CI of 66.9–90.2, specificity 51.4% with
95% CI of 34.0–68.6, PPV 70.0%, NPV 65.4%, AUC
0.734 with 95% CI of 0.627–0.823) and S3 vs. S0–S2
(sensitivity 81.1% with 95% CI of 64.8–92.0, specificity
57.1% with 95% CI of 42.2–71.2, PPV 57.7%, NPV
79.4%, AUC 0.752 with 95% CI of 0.647–0.839), respect-
ively. The AUC was higher for the diagnosis of S1–S3
vs. S0 compared with that of S2–S3 vs. S0–S1 (p =
0.011) and that of S3 vs. S0–S2 (p = 0.015). However, it
was not different for the diagnosis of S2–S3 vs. S0–S1
and that of S3 or not (p > 0.999).
Relationships in different body habitus groups
PDFF was positively correlated with CAP in all patients
(r = 0.486; 95% CI: 0.306, 0.633; p < 0.001) (Table 4). Ac-
cording to subgroup analysis, the correlation coefficient
between PDFF and CAP was 0.585 (95% CI: 0.302,
0.773) in the non-obese group (n = 33, p < 0.001) and
0.354 (95% CI: 0.093, 0.570) in the obese group (n = 53,
Table 2 Patient characteristics according to steatosis grades based on MR proton density fat fraction
Steatosis grades
S0 (n = 10) S1 (n = 25) S2 (n = 14) S3 (n = 37) p-value*
Age (y) 13 (9–17) 14 (7–18) 13 (10–18) 12 (9–18) 0.209
Female (n, %) 5 (50.0) 8 (32.0) 5 (35.7) 6 (16.2) 0.134†
BMI (kg/m2) 20.6 (14.7–25.9) 26.3 (18.0–38.5) 26.5 (19.2–30.9) 28.3 (19.3–40.6) 0.002
AWT (cm) 1.7 (1–2.9) 2.7 (1.3–4.3) 2.5 (1.8–3.2) 2.8 (1.8–4.7) 0.003
AST (U/L) 21.5 (17–26) 52 (12–241) 36 (17–197) 63 (25–179) < 0.001
ALT (U/L) 15 (8–28) 95 (8–430) 61 (22–234) 96 (23–346) < 0.001
Total bilirubin (mg/dL) 0.6 (0.3–0.8) 0.6 (0.3–1.2) 0.5 (0.3–1.6) 0.5 (0.3–0.9) 0.089
Albumin (g/dL) 4.4 (4.2–5.1) 4.6 (3.7–5.2) 4.5 (4.0–4.9) 4.6 (4.3–5.1) 0.249
ALP (IU/L) 217 (69–325) 152 (38–405) 201 (59–308) 242 (65–466) 0.032
Cholesterol (mg/dL) 161.5 (127–231) 184 (144–306) 205 (151–222) 191 (125–276) 0.044
TG (mg/dL) 91 (44–419) 117 (58–240) 144.5 (55–322) 158 (54–487) 0.045
HDL (mg/dL) 50.5 (26–66) 39 (26–70) 44 (28–50) 47 (30–65) 0.133
LDL (mg/dL) 79.1 (60.2–106.8) 117.6 (71.2–235.8) 128 (90.8–183) 107.8 (66.6–205) 0.010
PDFF (%) 3.5 (2.6–5.2) 13.9 (6.8–17) 19.5 (17.8–23.1) 33.7 (24–48) < 0.001
CAP (dB/m) 222.5 (157–311) 308 (216–400) 301 (271–384) 329 (272–399) < 0.001
The values are median (range) or number (percentage)
*Non-parametric method, Kruskal-Wallis test, was performed to compare groups, unless otherwise indicated
†Chi-square test was performed to compare groups. All the p-values of boldface are less than 0.05
Notes: AWT abdominal wall thickness, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, TG triglycerides, HDL high-density
lipoprotein, LDL low-density lipoprotein, PDFF proton density fat fraction, CAP controlled attenuation parameter
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p = 0.009), the difference of which was not statistically
significant (z = 1.30, p = 0.097) (Fig. 2).
With respect to AWT, male (2.61 ± 0.63 cm) had sig-
nificantly higher AWT than female did (2.39 ± 0.69; p =
0.045). PDFF was not correlated with AWT (Table 4).
However, CAP was positively correlated with AWT (r =
0.517; 95% CI: 0.343, 0.657; p < 0.001). In subgroup ana-
lysis, only CAP was positively correlated with AWT in
both the non-obese group (r = 0.549; 95% CI: 0.253,
0.751; p = 0.001) and obese group (r = 0.386; 95% CI:
0.129, 0.594; p = 0.004). AWT was not correlated with
PDFF in either the non-obese or obese group.
In the BMI30 group, CAP values were obtained using
M probe in 13 patients and XL probe in four patients.
The median values of the PDFF and CAP in BMI30
group patients were 19 and 20% in PDFF, and 326 dB/m
and 370 dB/m in CAP, obtained with M and XL probes,
respectively. PDFF was not correlated with CAP (r =
0.212; 95% CI: -0.300, 0.629; p = 0.413). AWT was not
correlated with PDFF (r = − 0.338; 95% CI: -0.704, 0.170;
p = 0.185) and CAP (r = 0.221; 95% CI: -0.291, 0.634; p =
0.394).
Discussion
NAFLD is becoming increasingly recognized as an im-
portant health problem for pediatric patients [19]. Be-
cause there is no established effective therapy, early risk
stratification for disease progression is considered an im-
portant component of patient management [20]. In this
retrospective study, we compared values for hepatic stea-
tosis in pediatric NAFLD cases obtained noninvasively
using PDFF and CAP techniques. Based on ROC analysis
for diagnosing hepatic steatosis grades using established
PDFF cutoff values, we suggest a CAP cutoff value of
241 dB/m for the presence of steatosis. However, CAP
cutoff values for steatosis grade 2 or higher were not re-
liable. Although there were moderate correlations be-
tween PDFF and CAP values in all patients (r = 0.486),
there was no correlation between PDFF and CAP in the
BMI30 group. CAP values were positively correlated
Fig. 1 Comparison of steatosis groups using controlled attenuation
parameter (CAP) value. (A and B) CAP values in each steatosis group
based on MR proton density fat fraction (PDFF) of whole group (a)
and divided by gender (b) are demonstrated in a box plot. Hepatic
steatosis grades 0–3 (S0-S3) were classified using the PDFF cutoff
values of 6, 17.5, and 23.3%. The mean and median CAP values were
228.4 and 222.5 dB/m in S0, 309 and 308 dB/m in S1, 313.2 and 301
dB/m in S2, and 332.7 and 329 dB/m in S3, respectively. The dash
line means the cutoff value of 241 dB/m to differentiate S0 vs. S1-S3.
(c) On receiver operating characteristic curve analysis, the optimal
cutoff value for diagnosis of S1-S3 vs. S0 was 241 dB/m with 98.7%
sensitivity (95% confidence interval [CI], 92.9–100.0), 80.0% specificity
(95% CI, 44.4–97.5), and 0.941 of area under the curve (95%
CI, 0.868–0.980)
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with AWT. Therefore, CAP can be a good screening tool
to diagnose the presence of steatosis in children, but is
probably limited during disease follow up or in children
with high BMI, though longitudinal data are lacking.
MRI-based hepatic fat quantification is useful in
pediatric patients not only for diagnosis and grading [9],
but also for treatment monitoring [21]. PDFF exhibits an
excellent correlation with hepatic steatosis, especially the
macrovesicular form, which is common in both adult
and pediatric NAFLD [22, 23]. PDFF also quantifies stea-
tosis of the whole liver, whereas liver biopsy only evalu-
ates a small portion of the liver. However, liver MRI
including PDFF in young children may require sedation
with additional examination time and cost. Therefore,
more convenient and cheaper diagnostic tests are re-
quired for screening and disease monitoring in patients
with NAFLD, especially in children.
TE is widely used to evaluate liver elasticity and has
been validated in large cohort studies for diagnosing and
staging liver fibrosis [24]. CAP calculates the attenuation
of ultrasonic signals acquired by TE, postulating that
ultrasound propagation is affected by fat tissues on the
path. CAP has been shown to have an excellent correl-
ation with actual liver fat percentage in non-to-mildly
obese patients with NAFLD [25] and can distinguish the
absence or presence of steatosis in adult chronic liver
disease [26, 27]. However, only one study with children
has demonstrated the ability of CAP to detect steatosis,
although differentiation among histopathologic grade of
steatosis was not successful with small number of pa-
tients and fair overlap [14]. In that study, the suggested
cutoff value of CAP for predicting steatosis was 225 dB/
m with 87% sensitivity, 83% specificity, and an AUC of
0.93, which is comparable to the cutoff of 241 dB/m de-
rived from our ROC analysis. In another study assessing
CAP compared with ultrasound grading and the other
imperfect gold standard in children, a cutoff point of
249 dB/m for predicting steatosis was identified with a
sensitivity of 72% and a specificity of 98–100% [28],
which is also comparable with our result.
In a prospective adult cohort study with PDFF as
the gold standard [5], the cut off values for PDFF
≥5% and ≥ 10% were 288 dB/m (AUC 0.80, 95% CI
0.70–0.90) and 304 dB/m (AUC 0.87, 95% CI 0.80–
0.94), respectively. In this study, the authors have
identified that demographical characteristics, such as
high BMI and high prevalence of type 2 diabetes,
may affect the accurate assessment of CAP. The por-
tion examined with the XL probe, which is reported
to show higher value of CAP than using M probe
[29], is also different with our study. A recent indi-
vidual patient meta-analysis of CAP for assessing hep-
atic steatosis with various etiologies has shown that
CAP values were influenced by several covariates, in-
cluding BMI and the presence of NAFLD or
non-alcoholic steatohepatitis (NASH), and suggested
cutoffs of 248 dB/m for grade 1, 268 dB/m for grade
2, and 280 dB/m for grade 3 steatosis [13]. However,
in another study from 2016, evaluating both PDFF
and CAP in adult NAFLD [12], the cutoff values for
hepatic steatosis grades 1, 2, and 3 were 5.2, 11.3,
and 17.1% for PDFF and 236 dB/m, 270 dB/m, and
302 dB/m for CAP, respectively. The cutoff values for
CAP and PDFF were both different in our study.
Moreover, discrimination among steatosis grades 1, 2,
and 3 with CAP was suboptimal in the present study.
Table 3 Diagnostic performance of CAP for hepatic steatosis grades (S0-S3)
Cutoff (dB/m) Sensitivity (%, 95% CI) Specificity (%, 95% CI) PPV (%) NPV (%) AUC (95% CI)
S0 vs. S1-S3 (≥6%) 241 98.7 (92.9–100.0) 80.0 (44.4–97.5) 96.2 87.5 0.941 (0.868–0.980)
S0-S1 vs. S2-S3 (≥17.5%) 299 80.4 (66.9–90.2) 51.4 (34.0–68.6) 70.0 65.4 0.734 (0.627–0.823)
S0-S2 vs. S3 (≥23.3%) 303 81.1 (64.8–92.0) 57.1 (42.2–71.2) 57.7 79.4 0.752 (0.647–0.839)
Notes: CAP, controlled attenuation parameter; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve
Table 4 Correlation values for hepatic steatosis in all patients, the non-obese group, obese group, and BMI30 (BMI > 30 kg/m2)
group
All patients
(n = 86)
Non-obese group
(n = 33)
Obese group
(n = 53)
BMI30 group
(n = 17)
r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value r (95% CI) p-value
PDFF CAP 0.486
(0.306–0.633)
< 0.001 0.585
(0.302–0.773)
< 0.001 0.354
(0.093–0.570)
0.009 0.212
(− 0.300–0.629)
0.413
AWT 0.179
(− 0.003–0.377)
0.099 0.318
(− 0.028–0.596)
0.071 −0.023
(− 0.300–0.249)
0.925 −0.338
(− 0.704–0.170)
0.185
CAP AWT 0.517
(0.343–0.657)
< 0.001 0.549
(0.253–0.751)
0.001 0.386
(0.129–0.594)
0.004 0.221
(− 0.291–0.634)
0.394
Notes: CI confidence interval, PDFF proton density fat fraction, CAP controlled attenuation parameter, AWT abdominal wall thickness. All the p-values of boldface
are less than 0.05
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One possible explanation for the discrepancy in cutoff
values is that the histopathologic nature of pediatric
NAFLD is different from that of adult disease. NAFLD
patterns are characterized by a zone 1 distribution of
steatosis, inflammation, and fibrosis in young children in
contrast to the most intense change around the central
vein (predominantly in zones 2 and 3) in adults [30].
This different pathologic distribution might affect the re-
sult of CAP on the basis of ultrasound technology.
Other possible reasons could be the higher BMI and
higher AST/ALT of patients in the present study, which
could affect CAP results, as demonstrated in a study in
adults [13]. Indeed, CAP values positively correlated
with AWT (r = 0.517, p < 0.001), while PDFF did not. It
could be from the difference of measurement way as
PDFF measures a proportion of fat molecules and CAP
measures physical properties of the liver. Whereas PDFF
only evaluate liver parenchyma to separate fat and water
signal, ultrasound signal on TE and CAP has no choice
but to pass through the subcutaneous fat layer between
TE probe and liver parenchyma. It is possible that the
subcutaneous fat layer might affect the CAP
measurement increasing ultrasound attenuation, espe-
cially in high BMI patients with increased AWT. A re-
cent systematic review evaluated the factors affecting
liver stiffness measurements using TE [31] and waist cir-
cumference was included as an affecting factor which is
considered to be the same context as the CAP and BMI
of this study. In addition, gender was included as covari-
ate since different adipose distribution by gender might
affect the result of CAP. In the present study, males had
significantly higher AWT than females did, contrary to
the previous study showing markedly higher subcutane-
ous thickness in females [32, 33]. Significantly higher
rate of obesity and metabolic syndrome in Korean boys
than in girls [3, 4] and small number of female patients
(n = 24) in this study might affect the discrepancy. Add-
itional studies with histopathologic correlations and ana-
lysis by gender will be needed to validate the effects of
pathologic differences and AWT on CAP.
There are intrinsic limitations of both TE and MRI for
the evaluation of NAFLD. Neither imaging modality can
reliably discriminate NASH from simple steatosis [34]. A
wide range of optimal cutoffs for the diagnosis of NASH
Fig. 2 A scatter plot of hepatic steatosis between PDFF and CAP. CAP values were positively correlated with PDFF in all patients (r = 0.486; 95%
confidence interval [CI]: 0.306, 0.633; p < 0.001). In subgroups according to body mass index (BMI), the r was 0.585 (95% CI: 0.302, 0.773; p < 0.001)
in the non-obese group (BMI < 95th percentile) and 0.354 (95% CI: 0.093, 0.570; p = 0.009) in the obese group (BMI≥ 95th percentile). However,
PDFF and CAP values were not correlated in the BMI30 (BMI > 30 kg/m2) group
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has been reported and likely depends on the prevalence
of advanced fibrosis in the study population [34]. In
addition, current imaging methods cannot detect the
lobular arrangement of steatosis, which is useful to dis-
tinguish the pediatric pattern of NAFLD [35].
This study also has several limitations. First, this was a
retrospective study that included patients suspected with
NAFLD who were referred by a pediatrician; thus, our
results may have been affected by selection bias. Second,
due to the lack of liver histopathologic data, we were un-
able to directly correlate and compare MRI and TE
values with histologic grades of hepatic steatosis. Al-
though PDFF based on MR imaging has demonstrated
good correlation with histological steatosis grade, there
were considerable overlap in PDFF results among steato-
sis grades [6, 7]. Therefore, histologic evaluation is still
needed to determine the effects of simple steatosis and
steatohepatitis on CAP values. Third, the number of pa-
tients, especially low proportion of the S0 group (n =
10), might be small to determine the optimal cutoff
point, resulting in uncertainty of estimated cutoff value.
However, in the retrospective study only including clin-
ically suspected NAFLD patients, this is a reasonable re-
sult because there is no need to perform PDFF and CAP,
without suspicion of NAFLD in pediatric patients. More-
over, the number of female patients is not enough for
additional analysis by gender. Fourth, because there were
no agreed criteria for severely obese patients in pediatric
field, a BMI30 cutoff was applied. Nevertheless, the pro-
portion of the BMI30 group was still low, so a further
study to focus on severely obese patients is required.
Conclusions
CAP can differentiate between the presence and absence
of hepatic steatosis using a cutoff value of 241 dB/m
with a sensitivity of 98.7% and a specificity of 80.0% in
pediatric patients with NAFLD. However, CAP was not
reliable in evaluating higher grade steatosis. Moreover,
caution should be exercised in interpreting CAP data in
obese children, especially in children with a BMI greater
than 30 kg/m2, from the effect of increased AWT.
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